2022
Rebleeding in peptic ulcer bleeding – a nationwide cohort study of 19,537 patients
Laursen S, Stanley A, Laine L, de Muckadell O. Rebleeding in peptic ulcer bleeding – a nationwide cohort study of 19,537 patients. Scandinavian Journal Of Gastroenterology 2022, 57: 1423-1429. PMID: 35853234, DOI: 10.1080/00365521.2022.2098050.Peer-Reviewed Original ResearchConceptsPeptic ulcer bleedingNationwide cohort studyUlcer bleedingHemodynamic instabilityCohort studyDuodenal ulcerHigh-risk endoscopic stigmataNon-ulcer lesionsHigh-risk stigmataLogistic regression analysisEndoscopic stigmataPersistent bleedingEndoscopic therapyFrequent complicationConsecutive patientsSuch patientsPrognostic consequencesHigh riskPatientsInterventional radiologyBleedingTwo-fold increaseMortalityUlcersStrongest predictor
2012
Corrigendum: Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Laine L, Kivitz A, Bello A, Grahn A, Schiff M, Taha A. Corrigendum: Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal Of Gastroenterology 2012, 107: 1272. DOI: 10.1038/ajg.2012.244.Peer-Reviewed Original Research
2011
Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS. Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal Of Gastroenterology 2011, 107: ajg2011443. PMID: 22186979, PMCID: PMC3321505, DOI: 10.1038/ajg.2011.443.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsChi-Square DistributionDouble-Blind MethodDrug CombinationsDuodenal UlcerEndoscopy, GastrointestinalFamotidineFemaleHumansIbuprofenMaleMiddle AgedProportional Hazards ModelsRisk FactorsStomach UlcerTreatment OutcomeConceptsPrimary end point analysisNon-steroidal anti-inflammatory drugsUpper GI ulcersDuodenal ulcerGI ulcersGastric ulcerEnd-point analysisDaily non-steroidal anti-inflammatory drugsH. pylori stool testDouble-blind randomized trialsMultiple potential risk factorsReduction of gastricSingle-tablet combinationUpper gastrointestinal ulcersDouble-blind trialProportional hazards analysisPotential risk factorsAnti-inflammatory drugsBaseline endoscopyREDUCE studyStudy endoscopyTablets thriceUlcer complicationsStool testRandomized trials
2008
Systematic Review of the Predictors of Recurrent Hemorrhage After Endoscopic Hemostatic Therapy for Bleeding Peptic Ulcers
Elmunzer BJ, Young SD, Inadomi JM, Schoenfeld P, Laine L. Systematic Review of the Predictors of Recurrent Hemorrhage After Endoscopic Hemostatic Therapy for Bleeding Peptic Ulcers. The American Journal Of Gastroenterology 2008, 103: ajg2008521. PMID: 18684171, DOI: 10.1111/j.1572-0241.2008.02070.x.Peer-Reviewed Original ResearchConceptsEndoscopic therapyIndependent predictorsRecurrent hemorrhageProspective studySystematic reviewIntensive care unit observationLarge ulcer sizePosterior duodenal ulcerSecond-look endoscopyEndoscopic hemostatic therapySignificant independent predictorsPrespecified inclusion criteriaComorbid illnessesHemodynamic instabilityHemostatic therapyDuodenal ulcerEndoscopic predictorsPrimary outcomeUlcer sizeMultivariable analysisPooled ratePeptic ulcerClinical managementBibliographic database searchInclusion criteria
2003
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study
Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003, 52: 820. PMID: 12740337, PMCID: PMC1773685, DOI: 10.1136/gut.52.6.820.Peer-Reviewed Original ResearchConceptsNon-selective non-steroidal antiinflammatory drugsGastroduodenal ulcersAdverse eventsRheumatoid arthritisLess gastrointestinal damageSecondary end pointsClinical adverse eventsDouble-blind studyRheumatoid arthritis patientsLog-rank testNon-steroidal antiinflammatory drugsGastroduodenal erosionsCumulative incidenceGastrointestinal damageArthritis patientsDuodenal ulcerLifetable analysisOverall incidenceSelective cyclooxygenaseAntiinflammatory drugsLower incidenceBlind studyMean changeTreatment groupsPlaceboBismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistance
2002
Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies
Sugg J, Laine L. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. The American Journal Of Gastroenterology 2002, 97: 2992. PMID: 12492181, DOI: 10.1111/j.1572-0241.2002.07116.x.Peer-Reviewed Original ResearchConceptsPersistent H. pyloriErosive esophagitisGERD symptomsH. pyloriSymptomatic GERDPersistent infectionDouble-blind prospective studyDouble-blind prospective trialGastroesophageal reflux disease symptomsCompletion of therapyDuodenal ulcer diseaseGastroesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyWorsening of symptomsEnd of therapyRapid urease testBlind prospective studyPylori eradicationPylori therapyReflux diseaseRegurgitation scoreProspective trialDuodenal ulcerUlcer disease
2000
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials
Laine L, Fennerty M, Osato M, Sugg J, Suchower L, Probst P, Levine J. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. The American Journal Of Gastroenterology 2000, 95: ajg20001583. PMID: 11151867, DOI: 10.1111/j.1572-0241.2000.03349.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmoxicillinClarithromycinDouble-Blind MethodDrug Administration ScheduleDrug Resistance, MicrobialDrug Therapy, CombinationDuodenal UlcerEsomeprazoleFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedPenicillin ResistancePenicillinsProspective StudiesProtein Synthesis InhibitorsProton Pump InhibitorsConceptsEradication rateClarithromycin resistanceDaily esomeprazoleTriple therapyDuodenal ulcerProton pump inhibitor-based triple therapyTen-day triple therapyHelicobacter pylori eradication therapyEmergent resistanceH. pylori-positive patientsInhibitor-based triple therapyDouble-blind trialTreat eradication ratesCompletion of therapyPylori eradication therapyPylori-positive patientsSeparate randomized trialsAntibiotic resistanceDaily amoxicillinUS multicenterEradication therapyRandomized trialsHelicobacter pyloriTherapyEsomeprazolePrevalence of active duodenal ulcer in H. pylori-positive patients with past history of duodenal ulcer and relationship to symptoms
Laine L, Sugg J, Probst P, Malone T, Neil G. Prevalence of active duodenal ulcer in H. pylori-positive patients with past history of duodenal ulcer and relationship to symptoms. Gastroenterology 2000, 118: a1264. DOI: 10.1016/s0016-5085(00)80899-9.Peer-Reviewed Original ResearchDuodenal ulcerH. pylori-positive patients
1998
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials
Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. The American Journal Of Gastroenterology 1998, 93: ajg1998488. PMID: 9820381, DOI: 10.1111/j.1572-0241.1998.00602.x.Peer-Reviewed Original ResearchConceptsDuodenal ulcer diseaseTriple therapyEradication rateUlcer diseaseH. pylori-infected patientsDaily triple therapyDays of omeprazoleDuodenal ulcer historyProtocol cure ratesProtocol eradication ratesTreat eradication ratesHelicobacter pylori eradicationPylori-infected patientsOAC patientsStudy medicationTreat populationUlcer historyPylori eradicationStudy drugAdverse eventsTwice DailyControlled TrialsDuodenal ulcerCure ratePatientsHas the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated?
Laine L, Hopkins R, Girardi L. Has the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated? The American Journal Of Gastroenterology 1998, 93: 1409. PMID: 9732917, DOI: 10.1111/j.1572-0241.1998.452_a.x.Peer-Reviewed Original ResearchConceptsH. pylori eradicationH. pylori therapyUlcer recurrencePylori eradicationPylori therapyH. pylori cureNon-NSAID ulcersCompletion of therapyHelicobacter pylori therapyUse of NSAIDsDuodenal ulcer patientsNorth American trialsUlcer recurrence rateHigh methodological qualityEndoscopic biopsy testsReview of abstractsEndoscopic followUlcer patientsDuodenal ulcerRelevant trialsRecurrence rateStudy inclusionOdds ratioCommon odds ratioMethodological qualityUS double‐blind, controlled trials of omeprazole and amoxycillin for treatment of Helicobacter pylori
Laine, Johnson, Suchower, Ronca, Hwang, Neil. US double‐blind, controlled trials of omeprazole and amoxycillin for treatment of Helicobacter pylori. Alimentary Pharmacology & Therapeutics 1998, 12: 377-382. PMID: 9690729, DOI: 10.1046/j.1365-2036.1998.00303.x.Peer-Reviewed Original ResearchConceptsH. pylori eradicationDual therapyEradication ratePylori eradicationDuodenal ulcerControlled TrialsHelicobacter pylori eradication ratesOmeprazole/amoxycillinPylori eradication ratesCompletion of therapyActive duodenal ulcerH. pylori diagnosisEndoscopic biopsy testsAmoxycillin resistanceAmoxycillin therapyAdverse eventsAmoxycillinTherapyHelicobacter pyloriOmeprazolePatientsBiopsy testsProtocol analysisUlcersTrials
1996
Nonsteroidal Anti-Inflammatory Drug Gastropathy
Laine L. Nonsteroidal Anti-Inflammatory Drug Gastropathy. Gastrointestinal Endoscopy Clinics Of North America 1996, 6: 489-504. PMID: 8803564, DOI: 10.1016/s1052-5157(18)30351-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGastrointestinal complicationsSubepithelial hemorrhageNonsteroidal anti-inflammatory drug gastropathyDevelopment of NSAIDUpper abdominal symptomsGastric outlet obstructionHalf of patientsPost-treatment biopsiesH. pylori infectionReactive gastritisAbdominal symptomsMajor bleedingMinor bleedingNSAID useUlcer complicationsGastrointestinal bleedingNSAID ingestionNSAID gastropathyOutlet obstructionDuodenal ulcerGastric erosionsHistologic gastritisGastric lesionsGastric ulcerPeptic ulcer
1993
HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA
Laine L. HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA. Gastroenterology Clinics Of North America 1993, 22: 117-125. PMID: 8449561, DOI: 10.1016/s0889-8553(21)00267-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsH. pylori prevalenceGastric ulcerHistologic gastritisH. pyloriGastric injuryPylori prevalenceDuodenal ulcerGastric mucosaNoxious agentsInflammatory cell infiltrateH. pylori infectionNSAID usersCell infiltratePylori infectionDuodenal contentsNSAIDsUlcersGross injuryGastritisPatientsHelicobacter pyloriPyloriInjuryMucosaPrevalence
1992
Endoscopic injection reduced further bleeding and need for surgery in patients with bleeding duodenal ulcers
Laine L. Endoscopic injection reduced further bleeding and need for surgery in patients with bleeding duodenal ulcers. Annals Of Internal Medicine 1992, 117: 39. DOI: 10.7326/acpjc-1992-117-2-039.Commentaries, Editorials and Letters